États-Unis · Places boursières & cours · Nasdaq

Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance

Publié par Nasdaq · États-Unis il y a 1 h

(RTTNews) - Telix Pharmaceuticals Ltd. (TLX), a commercial-stage company, reported a 19% increase in group revenue and highlighted key operational achievements for the third…

Lire l'article complet sur Nasdaq Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.nasdaq.com)

Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance

À lire aussi

How Bad Would It Get If China Blocks Rare Earths to America?

Understanding Prediction Markets Before You Trade

Stacks (STX) Volatility: No Clear Catalyst for 5.1% Drop

State of the Options Industry Q3 2026: Volume Growth Concentrated in Index and ETF Options

Developer’s guide to implementing MCP apps in Gemini

Telix Pharma Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance

Partager

À lire aussi

How Bad Would It Get If China Blocks Rare Earths to America?

Understanding Prediction Markets Before You Trade

Stacks (STX) Volatility: No Clear Catalyst for 5.1% Drop

State of the Options Industry Q3 2026: Volume Growth Concentrated in Index and ETF Options

Developer’s guide to implementing MCP apps in Gemini